CKD is the disorder characterized by abnormalities in structure and function of kidneys which is present for 3 months or more.
In this presentation Definition , Epidemiology , Etiology , Pathophysiology, Signs & symptoms , Diagnosis and Management of CKD is given .
The author is currently pursuing M Pharma pharmacy practice at Department of pharmaceutical sciences , University of kashmir
1 of 15
Download to read offline
More Related Content
CHRONIC KIDNEY DISEASE (CKD) for medical students.pptx
2. CKD is defined as abnormalities in
kidney St. or fun., present for 3
months or longer, with implications on
health. Structural abnormalities
include albuminuria of more than
30mg/day, presence of hematuria or
red cell casts in urine sediment,
electrolyte imbalance. An
abnormalities in kidney function is
usually indicated by decrease in GFR.
3. KDIGO CATEGORY GFR (ml/min/1.73m*
2)
TERMS CORRESPONDING
KDOQI CATEGORY
G1 >90 NORMAL OR HIGH STAGE 1 CKD
G2 60-89 MILDLY DECREASED STAGE 2 CKD
G3a 45-59 MILDLY
MODERATELY
DECREASED
STAGE 3 CKD
G3b 30-44 MODERATELY
SEVERLY DECREASED
STAGE 3 CKD
G4 15-29 SEVERLY DECREASED STAGE 4 CKD
G5 <15 KIDNEY FAILURE STAGE 5 CKD (ESRD IF
REQUIRING DIALYSIS)
TABLE 1: CLASSIFICATION OF CKD ON THE BASIS OF GFR CITERIA (kdigo &
kdoqi)
4. EPIDEMIOLOGY
- According to NHANES data , prevalence of CKD ( not
including ESRD) in US is estimated to affect over 25 M
people,13 % of US population.
- CKD is more likely in individuals over 60 yrs of age and in
those with DM,HTN & CVD.
- In National kidney foundations KEEP study over 32,000 0f
124,041 participants (25%) had CKD.
- Incidence of ESRD are higher in African Americans (3.4
times) & native Americans (0.5 times) compared with
whites & 1.5 times greater in Hispanics than in non
Hispanics.
- In patients 75 yrs of age and older ,the incidence and
prevalence rates increase from 12% -44% from year 2000.
- Mortality in CKD population is 59% higher than in non
5. ETIOLOGY
1) SUSCEPTIBILITY FACTORS
-Advanced age
-Low income or education
-Racial minority status
-Reduced kidney mass
-Low birth weight
-Family history of CKD
-Dyslipidemia
2) INITIATON FACTORS
These are the conditions that directly result in kidney damage and are modifiable by
pharmacological therapy.
-DM (45% OF ESRD)
-HTN (29% OF ESRD)
-GLOMERULONEPHRITIS (3RD LEADING CAUSE OF ESRD)
-POLYCYSTIC KIDNEY DISEASE
-WEGENERS GRANULOMATOSIS
-HIV INDUCED NEPHROPATHY
6. 3) PROGRESSION FACTORS:
Progression factors are those associated with further
decline in kidney function. Persistence of underlying
initiation factors themselves serve as important factors of
progression of CK disease
Other factors associated with progression include those
that may consequent to underlying kidney disease (e.g.
HTN ,proteinuria ) or those independent of underlying
kidney disease (e.g. smoking ,obesity)
8. DIABETES
HTN
GLOMERULONEPHRITIS REDUCED NO. OF
STRUCTURAL & FUN. PCKD NEPHRONS
CHANGES IN
SURVIVING
NEPHRONS
(HYPERTROPHY)
SCLEROSIS OF
HYPERFILTRATION
NEPHRONS INCREASE IN
intraglomerula
r pressure
INCREASE IN URINARY
ALBUMIN EXCREATION &
9. CKD- RELATED MINERAL & BONE DISORDER
KIDNEY
FAILURE
DECREASE
D GFR
DECREASED
ACTIVATION OF
VITAMIN D
DECREASED P04
EXCRETION
IMPAIRED Ca ABSORPTION FROM
GUT
DECREASED SERUM
Ca
INCREASE PTH
BONE DEMINERALIZATION
INCREASE
SERUM Ca
INCREASE
SERUM PO4
10. ANEMIA OF CKD
The primary cause of anemia in ckd patients
is due to decrease in production of
erythropoietin(glycoprotein hormone
necessary for erythropoiesis)by interstitial
fibroblasts in the renal cortex of the kidney
where approx. 90% of production occurs.
Iron deficiency is common in individuals with
stage 5 CKD due to decreased GI absorption
of iron, inflammation , blood loss from
hemodialysis and increased demands for ESA
11. SYMPTOMS
1) UREMIC SYMPTOMS such as fatigue , weakness , shortness of
breath , mental confusion ,nausea ,vomiting , bleeding and
loss of appetite.
2) Itching
3) Cold intolerance
4) Weight gain from accumulation of fluid
5) Peripheral neuropathies
SIGNS
1) Edema
2) Changes in urine output (vol and consistency)
3) Foaming of urine (indication of proteinuria)
4) Abdominal distension.
12. DIAGONOSIS
LABORATORY TESTS:
- DECREASED: GFR , BICARBONATE (METABOLIC ACIDOSIS) , Hb
/HEMATOCRIT , VIT. D LEVELS , ALBUMIN , GLUCOSE &
CALCIUM (in early stages of CKD).
- INCREASED : SERUM CREATININE , CYSTATIN C , BLOOD UREA
NITROGEN , POTASSIUM , PHOSPHORUS , PTH , LDL &
TRIGLYCERIDES AND Ca (ESRD).
OTHER DIAGNOSTIC TESTS :
- URINE ANALYSIS ( HEMATURIA , RBC & WBC CASTS )
- STRUCTURAL ABNORMALITIES SUCH AS PCKD , RENAL
MASSES OR SMALL KIDNEYS ARE DETECTED BY
IMAGING STUDIES LIKE USG , CT , MRI.
13. NON- PHARMACOLOGICAL MANAGEMENT
- DIET : Restrict dietary protein < 40 g/day ,
Restrict Na+ ,K+ & PO4 intake , avoid potassium
containing foods e.g. BANANA.
-WATER AND ELECTROLYTE BALANCE :
Daily fluid intake = Previous days urine output +
600 ml (for insensible losses)
-Daily weighing.
-General health advices like exercise and
smoking cessation.
-Avoid nephrotoxins e.g. NSAIDs , Herbal
14. PHARMACOLOGICAL TREATMENT
1) DIABETES WITH CKD : Target BP : < 140 /90 mmHg if UAE <30 mg/day ,<
130/80 mmHg if UAE > 30 mg/day
*For T1DM- Insulin shots
*For T2DM Metformin : if eGFR is >30 ml/min/1.73m^2 IF < 30 then dicountinue.
GLP-1 RECEPTOR AGONISTS EXANETIDE , LIRAGLUTIDE.
2)CKD with HTN: BP target same as DM with ckd
*ACEi: CAPTROPRIL , ENALAPRIL , LISINOPRIL.
*ARBs: LOSARTAN , VALSARTAN , TELMISARTAN.
*CCBS : Nifedipine ,nicardipine, amlodipine ,diltiazem , verapamil
*LOOP DIURETICS (IF EDEMA IS PRESENT) :
*THIAZIDE DIURETICS :
3) ANEMIA OF CKD
*IRON SUPPLEMENTATION : ORAL (FERROUS SULFATE , FERROUS FUMARATE , FERROUS
GLUCONATE) , IV (IRON DEXTRAN ,SODIUM FERRIC GLUCONATE)
*ERYTHROPOIETIC STIMULATING AGENTS: EPOETIN alfa and DARBEPOETIN
4) CKD-MBD
PHOSPHATE BINDING AGENTS : CALCIUM CARBONATE, CALCIUM ACETATE , SEVELAMER
CARBONATE.